Shanghai Bintie Biotechnology
A clinical-stage biomedical technology innovation enterprise
About Shanghai Bintie Biotechnology
Immuxell is a biotechnology company specializing in the development of bispecific T Cell Engagers to combat cancer. Utilizing its proprietary TETHER platform, Immuxell creates off-the-shelf biologics that redirect and activate the body's own T cell immune response towards cancer cells expressing specific oncogenic driver targets. The company's advanced affinity maturation capabilities and biotherapeutic technologies produce T Cell Engagers with balanced CD3 binders and extended half-life, aiming for sustained T cell responses against solid tumors. Immuxell serves patients with advanced solid tumors, leveraging scientific advancements in gene editing, synthetic biology, and cell therapies to deliver potentially curative treatments. The business operates in the oncology therapeutics market, primarily targeting oncogenic driver mutations like KRAS, which are crucial for tumor growth and maintenance. Immuxell generates revenue through the development and commercialization of its proprietary therapies, as well as potential partnerships and licensing agreements.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 17.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Oct 2023 | $14M | $55M | Huangpu Pharmaceutical Fund · SDIC Venture Capital · GSR United Capital | ↗ |
Growth signals
Latest recorded traffic for Shanghai Bintie Biotechnology is 1.2K monthly website visits, up 150% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Shanghai Bintie Biotechnology in its local ecosystem
The Shanghai Bintie Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
- HFHuangpu Pharmaceutical Fund
SDIC Venture Capital
GSR United Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Shanghai Bintie Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Shanghai Bintie Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









